Alnylam pharmaceuticals reports first quarter 2023 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the first quarter ended march 31, 2023 and reviewed recent business highlights. “the first quarter of 2023 saw continued strong commercial execution, driven by the ongoing launch of amvuttra, delivering robust 48% growth in total product sales compared with the first quarter 2022. we also made significant progress with our.
ALNY Ratings Summary
ALNY Quant Ranking